NovoCure (NAS:NVCR) Days Inventory

: 94.13 (As of Mar. 2023)

View and export this data going back to 2015. Start your Free Trial

Days Inventory is also known as Days Sales of Inventory (DSI). NovoCure's Average Total Inventories for the three months ended in Mar. 2023 was $30.5 Mil. NovoCure's Cost of Goods Sold for the three months ended in Mar. 2023 was $29.6 Mil. Hence, NovoCure's Days Inventory for the three months ended in Mar. 2023 was 94.13.

The historical rank and industry rank for NovoCure's Days Inventory or its related term are showing as below:

NVCR' s Days Inventory Range Over the Past 10 Years
Min: 82.37 Med: 97.77 Max: 156.13
Current: 91.6

During the past 10 years, NovoCure's highest Days Inventory was 156.13. The lowest was 82.37. And the median was 97.77.

NVCR's Days Inventory is ranked better than
84.54% of 776 companies
in the Medical Devices & Instruments industry
Industry Median: 175.84 vs NVCR: 91.60

NovoCure's Days Inventory increased from Mar. 2022 (88.05) to Mar. 2023 (94.13). It might indicate that NovoCure's sales slowed down.

Inventory Turnover measures how fast the company turns over its inventory within a year. NovoCure's Inventory Turnover for the three months ended in Mar. 2023 was 0.97.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. NovoCure's Inventory-to-Revenue for the three months ended in Mar. 2023 was 0.25.

NovoCure Days Inventory Historical Data

The historical data trend for NovoCure's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Inventory

101.64

95.27

87.60

82.37

85.48

NovoCure Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Days Inventory																88.05	93.83	86.38	88.71	94.13

Competitive Comparison

For the Medical Devices subindustry, NovoCure's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

NovoCure Days Inventory Distribution

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Days Inventory distribution charts can be found below:

* The bar in red indicates where NovoCure's Days Inventory falls in comparison to its industry or sector. The grey bar indicates the Days Inventory's extreme value range as defined by GuruFocus.

NovoCure Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

NovoCure's Days Inventory for the fiscal year that ended in Dec. 2022 is calculated as

	Days Inventory (A: Dec. 2022 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2021 )	+	Total Inventories (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (24.427	+	29.376)	/	2 )	/	114.867	*	365
=	26.9015					/	114.867	*	365
=	85.48

NovoCure's Days Inventory for the quarter that ended in Mar. 2023 is calculated as:

	Days Inventory (Q: Mar. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Dec. 2022 )	+	Total Inventories (Q: Mar. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2023 )	*	Days in Period
=	( (29.376	+	31.723)	/	2 )	/	29.614	*	365 / 4
=	30.5495					/	29.614	*	365 / 4
=	94.13

NovoCure (NAS:NVCR) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

NovoCure's Inventory Turnover for the three months ended in Mar. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	29.614	/	30.5495
	=	0.97

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

NovoCure's Inventory to Revenue for the three months ended in Mar. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	30.5495	/	122.182
	=	0.25

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

NovoCure Days Inventory Related Terms

Thank you for viewing the detailed overview of NovoCure's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure (NAS:NVCR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (NAS:NVCR) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

NVCR:Mexico 038:Germany

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.

Executives

Arye Barak Ben	officer: General Counsel	TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905
William Patrick Burke	officer: Chief Human Resources Officer	195 COMMERCE WAY, PORTSMOUTH NH 03801
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Ashley Cordova	officer: Chief Financial Officer	20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Frank X Leonard	officer: Chief Development Officer	20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Uri Weinberg	officer: Chief Science Officer	NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Ely Benaim	officer: Chief Medical Officer	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Pritesh Shah	officer: Chief Commercial Officer	C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Sherilyn S Mccoy	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
David Hung	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Martin J. Madden	director	C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043
Steve Futrell	10 percent owner	780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017
Frances Janis	10 percent owner	780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017
Michael D Granoff	10 percent owner	780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017